Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

Popular Mechanics recognizes three NSF-funded projects with innovation Breakthrough Awards

Popular Mechanics recognizes three NSF-funded projects with innovation Breakthrough Awards

UCI scientists receive CIRM grants to improve stem cell treatments

UCI scientists receive CIRM grants to improve stem cell treatments

Retina Implant's first clinical trial results presented at 2010 AAO annual meeting

Retina Implant's first clinical trial results presented at 2010 AAO annual meeting

Beta carotene improves vision in people with Incurable Retinal Disease Retinitis pigmentosa: Report

Beta carotene improves vision in people with Incurable Retinal Disease Retinitis pigmentosa: Report

Researchers receive NIH award to investigate regenerative potential of retinal cells

Researchers receive NIH award to investigate regenerative potential of retinal cells

Retina Implant AG presents clinical data of successful subretinal electronic implants

Retina Implant AG presents clinical data of successful subretinal electronic implants

ACT receives patent for RPE cells to treat retinal degeneration

ACT receives patent for RPE cells to treat retinal degeneration

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

Non-viral gene therapy delays onset of eye disease

Non-viral gene therapy delays onset of eye disease

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Neurobiologists discover potential cure for degenerative vision diseases

Neurobiologists discover potential cure for degenerative vision diseases

Valproic acid halts vision loss in patients with retinitis pigmentosa

Valproic acid halts vision loss in patients with retinitis pigmentosa

University of Louisville ophthalmology professor receives $60,000 RPB Special Scholar Award

University of Louisville ophthalmology professor receives $60,000 RPB Special Scholar Award

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

International Stem Cell congratulates ACT on the issuance of its recent patent

International Stem Cell congratulates ACT on the issuance of its recent patent

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa